Table 4 Cardiotoxicity diagnosis, management, monitoring and referral to cardiac or palliative care (Medical Record Review cohort only)
From: Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
| Cardiotoxicity diagnosis and management | N = 46 |
| Referred to cardiologist (any) | 27 (59) |
| Referred to cardiologist prior to first chemotherapy | 7 (15) |
| Method of cardiotoxicity diagnosisa | |
| ECG | 6 (13) |
| MUGA | 5 (11) |
| Echocardiography (LVEF < 53%) | 44 (96) |
| Angiography | 4 (9) |
| Biomarkers | Not documented |
| Monitoring during and after anticancer therapy | |
| HbA1c | 1 (2) |
| Glucose | 10 (22) |
| Systolic Blood Pressure (mmHgb) | 24 (52) |
| Diastolic Blood Pressure (mmHg) | 22 (48) |
| HR (beats per minute) | 20 (44) |
| Heart failure multidisciplinary care/cardiac rehabilitation | |
| Referred to HF clinic or nurse | 22 (48) |
| Saw a HF nurse | 18 (39) |
| Referred to cardiac rehabilitation | 8 (17) |
| Attended cardiac rehabilitation | 6 (13) |
| Referred to clinical pharmacologist | 5 (11) |
| Saw a clinical pharmacologist | 4 (9) |
| Cancer survivorship or palliative care | |
| Referred to palliative care | 10 (22) |
| Received palliative care | 5 (11) |
| Cancer survivorship program referred | 1 (2) |
| Cancer survivorship program seen | 2 (4) |